By Q1 2026, 83% of all U.S
Abstract The incretin hormone, glucagon-like peptide-1 (GLP-1), stimulates insulin secretion and forms the basis of a new drug class for diabetes treatment
By supporting healthy sleepwake cycles, stress adaptation, immune modulation, and inflammatory balance , this peptide blend contributes to improved mental clarity, physical performance, skin quality, and overall vitality as part of a longevity-focused wellness routine
AKA the original patch brand offering great product for well over a decade
This helps preserve the muscle youve worked so hard to keep
The headline On Thursday 21 May 2026, Eli Lilly announced that participants in TRIUMPH-1, the first Phase 3 trial of retatrutide in obesity, lost an average of 28.3% of their body weight at 80 weeks on the 12 mg dose, with 45.3% losing at least 30% of their starting weight [1]